Givosiran increases quality of life, reduces attacks in acute hepatic porphyria
LONDON — Long-term givosiran treatment provided sustained benefit and improved quality of life among patients with acute hepatic porphyria, according to research presented at the International Liver Congress.“Acute hepatic porphyria is a rare genetic disorder that causes acute neurovisceral symptoms caused by defects in hepatic heme biosynthesis leading to accumulation of neurotoxic heme intermediates 5-aminolevulinic acid and porphobilinogen, which can be life-threatening in a small proportion of patients. It can also lead to chronic debilitating symptoms in a subtype of patients,”Read More
